Poolbeg Pharma PLC (LSE:POLB), a clinical-stage biopharmaceutical company listed on the London Stock Exchange, has announced the successful completion of an upsized and oversubscribed share offering that raised approximately £4.865 million in gross proceeds. The fundraising extends its operational runway through to 2027.
IXICO PLC (LSE:IXI, OTC:PHYOF)has released its first-half performance for the six months ending 31 March 2025, with the neuroscience imaging specialist saying it remains on course to meet or exceed its full-year expectations. The company credited its strategic focus on commercial and technological execution …
Poolbeg Pharma PLC (LSE:POLB)has announced plans to raise approximately £4.1 million through a combination of share placing and subscriptions, aiming to accelerate the development of two of its key experimental drug programmes. The funding is expected to support upcoming clinical trials focused on cancer …
Arecor Therapeutics plc (AIM: AREC)has announced a new collaboration with US-based Skye Bioscience (Nasdaq: SKYE) to develop a higher concentration formulation of nimacimab, a monoclonal antibody currently under investigation for the treatment of obesity and related metabolic conditions.
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has announced progress in securing intellectual property protection for its core gene therapy technology in Japan, with the country’s patent office advancing a key application to the national examination stage.
In a strategic move to bolster its liver disease portfolio, GSK plc (LSE:GSK) has announced the acquisition of efimosfermin alfa, a promising investigational treatment for steatotic liver disease (SLD), from Boston Pharmaceuticals. The deal, valued at $2 billion, includes an upfront payment of $1.2 …
GSK (LSE:GSK)has made a positive start to 2025, posting growth in sales, profits, and earnings, with performance underpinned by its thriving Specialty Medicines segment and strategic investments in pipeline advancement.
Smith+Nephew plc (LSE:SN, NYSE:SNN)reported growth for the first quarter ended 29 March 2025, driven by operational improvements and new product launches, despite external challenges including continued headwinds from China and one fewer trading day compared to the prior year.
Shares in AstraZeneca PLC (LSE:AZN) dropped by 4% in early London trading following the release of its first-quarter 2025 results, as a slight miss on revenue forecasts overshadowed stronger-than-expected earnings and a standout performance in its oncology segment.
Reckitt Benckiser Group PLC reported a resilient performance in the first quarter of 2025, with like-for-like (LFL) net revenue for Core Reckitt increasing by 3.1%. This growth was primarily fuelled by a performance from its Powerbrands, notably Germ Protection (up 7.5%) and Intimate Wellness …